A large body of preclinical and clinical data concerning the new semisynthetic vinca alkaloid
vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre …

Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre
Médicament, Paris, France) is a novel semisynthetic vinca alkaloid with antitumor activity in …

OBJECTIVE: To review the chemistry, pharmacology, pharmacokinetics, clinical activity,
adverse effects, and dosage and administration guidelines for vinorelbine in the treatment of …

Vinorelbine (navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre
Medicament, Paris, France), a novel semisynthetic vinca alkaloid, is the first drug approved …

Vinorelbine is a new semisynthetic vinca alkaloid. Data from in vitro and in vivo preclinical
studies suggest that vinorelbine is active in both small cell lung cancer (SCLC) and non …

Vinorelbine, a vinca alkaloid, was the first drug in over 20 years to be approved by the Food
and Drug Administration for treatment of advanced non-small cell lung cancer (NSCLC). The …

To evaluate the effectiveness of vinorelbine (NVB) in patients with non-small cell lung
cancer (NSCLC), a late Phase II study was conducted. A total of 80 patients with Stage III or …

Randomized clinical trials of vinorelbine (Navelbine; Burroughs Wellcome Co, Research
Triangle Park, NC; Pierre Fabre Médicament, Paris, France) as a single agent and in …

Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable
non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30 …

Vinorelbine (Navelbine') is a new, semisynthetic 5'Nor-vinca-alkaloid, modified on the
catharantine ring, developed by Pierre Fabre Medicament. Vinorelbine is as potent as the …